AOD-9604 vs ARA-290
Side-by-side comparison of key properties, dosing, and research.
- Summary
- AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
- ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
- Half-Life
- 30-45 minutes injectable; longer with nasal spray formulation
- ~2–4 hours (SC administration)
- Admin Route
- SubQ, Intranasal, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 300-600 mcg
- 4 mg (fixed dose)
- Frequency
- Once daily
- Once daily
- Key Benefits
- Selective fat loss without anabolic side effects
- No effect on blood glucose or insulin resistance
- Improved bioavailability over Fragment 176-191
- GRAS (Generally Recognized As Safe) status in Australia
- Potential cartilage repair and anti-inflammatory properties
- Does not suppress natural GH production
- Reduces neuropathic pain from small fiber neuropathy
- Anti-inflammatory without immune suppression
- Tissue protection after ischemia/reperfusion injury
- Promotes nerve fiber regeneration
- Improves symptoms of sarcoidosis-associated neuropathy
- May reduce insulin resistance and improve metabolic health
- Shown to improve autonomic neuropathy symptoms
- Side Effects
- Localized injection site reactions
- Headache (rare)
- Hypoglycemia risk in combination with insulin (very rare)
- Injection site reactions
- Mild fatigue at initiation
- Transient warm sensation post-injection
- Rare: mild headache
- Stacks With
- —
- —